Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Date:6/23/2011

AMSTERDAM, June 24, 2011 /PRNewswire/ --


 

- Dossier Re-Examination Process Initiated

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera® (alipogene tiparvovec) as a potential therapy for Lipoprotein Lipase Deficiency ("LPLD"). Following a recent meeting with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), AMT has been notified that, at this time, Glybera is not approvable.

Subsequent to a review of the CHMP's letter, AMT believes that Glybera can receive a positive opinion subject to generating additional data from existing patients. AMT has therefore decided to ask for a re-examination of the clinical data package.

"From what we know today, despite the disappointment, we believe that there is an indication from the CHMP that Glybera could receive approval and that the current opinion at this time is a reflection of insufficient proof of clinical benefit of Glybera as a result of low patient numbers measured for chylomicron handling for at least 12 months post treatment. The CHMP also indicated that if certain additional data from already treated patients would confirm current results by the end of 2011, an approval may be possible," noted Jörn Aldag, CEO of AMT. "In the dossier, we provided important data showing Glybera is safe and prevents episodes of pancreatitis, the major clinical complication of LPLD. We appreciate the CHMP's responsibility for caution on such an advanced therapy, so we will work diligently to generate more information and, we hope, ensure that Glybera will still reach patients."

Next steps

As part of the MAA, AMT presented data to the CHMP on Glybera showing evidence in reducing the risk of pancreatitis. Also, the company demonstrated a clear signal of patients' ability to b
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
2. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
3. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
4. Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis
5. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
6. ImaginAb, Inc. Announces Availability of Custom Protein Radiolabeling Services for Molecular Imaging
7. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
8. The World Leader in Molecular Breast Imaging to Premiere Largest Detector in the Industry
9. Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument
10. Latest Clinical Evidence Supports Promising Outlook for Low-Dose Molecular Breast Imaging (MBI)
11. Cepheid Extends Rapid Molecular Diagnostics Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... quarter 2014 financial results after the Nasdaq market closes ... a live conference call and webcast to discuss its ... August 7, 2014 at 8:00 a.m. Eastern Time (5:00 ... live conference call by dialing 866-952-1907 (US) or 785-424-1826 ...
(Date:7/29/2014)... , July 29, 2014  Sysmex America, Inc., a ... systems technology, will feature an exhibit booth during the ... and Clinical Lab Expo in Chicago ... "We are extremely excited to exhibit at ... interact with our customers and continue the dialogue on ...
(Date:7/29/2014)... Apex Medical Corporation (Apex, TWSE: 4106), a leading ... announces that it is appealing the judgment of the Regional ... Germany that found the headgear of certain mask ... initiated invalidity challenges against various ResMed patents in major countries. ... and junk patents. ResMed filed the lawsuit ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Apex Continues Fighting Against Patents to Free Up Competition 2
... and BASEL, Switzerland, Nov. 15, 2010 Dalton ... created to provide clients with geographically diversified, fully ... of active pharmaceutical ingredients. In order ... efficiency, pharmaceutical development companies have been seeking Chemistry ...
... Nov. 12, 2010 Nephros, Inc. (OTC Bulletin Board: ... and marketing filtration products for therapeutic applications, infection control, ... three months ended September 30, 2010. ... prior year period. Reduced loss from operations by ...
Cached Medicine Technology:Dalton and Lonza Announce Co-operation to Provide Contract Chemistry Services and Manufacturing 2Dalton and Lonza Announce Co-operation to Provide Contract Chemistry Services and Manufacturing 3Nephros Reports 2010 Third Quarter Financial Results 2Nephros Reports 2010 Third Quarter Financial Results 3Nephros Reports 2010 Third Quarter Financial Results 4Nephros Reports 2010 Third Quarter Financial Results 5Nephros Reports 2010 Third Quarter Financial Results 6
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle book review ... teaches people how to cure their nasal polyps ... the horrible truth about conventional treatments for nasal polyps. ... people will learn how to prevent symptoms related to ... , Nasal Polyps Treatment Miracle, as it is reviewed now ...
(Date:7/30/2014)... San Francisco, CA (PRWEB) July 30, 2014 ... charge capture and physician communication, launched an Observation ... performed in the hospital. pMD’s cardiology customers are ... and optimize revenue for their test interpretations for ... provider interprets tests in the hospital, the cardiology ...
(Date:7/29/2014)... Paul Mata, CEO of ‘Create Indestructible Wealth,’ ... 30 Days” E-book. The e-book includes a myriad of fast ... cash. Examples include downloading and utilizing specific phone apps ... people monetize the assets they didn't know they had like ... find in their garage. , After reading the e-book, ...
(Date:7/29/2014)... Ireland (PRWEB) July 30, 2014 Dignity ... the successful completion of a Phase I trial with ... (DGLA). , This study was a randomized, placebo-controlled, double-blind, ... assess the safety, pharmacokinetics and effect of food on ... the benign safety profile of DGLA following both single ...
(Date:7/29/2014)... (EA) a form of acupuncture where a ... acupuncture needles produces significant improvements in fatigue, ... weeks for early stage breast cancer patients experiencing ... inhibitors (AIs) to treat breast cancer. The results ... led by researchers at the Perelman School of ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3
... markets Aricept with Pfizer Inc. Aricept is already approved in ... but at present it was being tested in patients with ... Alzheimer's disease. ,But the shocking results show that ... clinical trial held at Japan's Eisai Co. ,There ...
... Dr Charles Reynolds at the University of Pittsburgh which was ... , The study’s main aim was to analyze the effect ... It is one of the longest studies ever in ... for longer periods, perhaps even for life, in patients who ...
... increasing number of addicts. Health authorities are warning of the ... with the consequences. ,Statistics show that about one ... Vincent's Hospital has recorded a five-fold increase in patients suffering ... in Australia. , The reason being that ice ...
... condition that affects millions of people. Scientists at the University ... leading to eczema and asthma. ,This gene produces ... outermost layers of the skin. It prevents bacteria and viruses ... to prevent the skin from drying. Reduction or absence of ...
... soon going to have more up market looking// medical stores ... supply free medicines to the patients., ,Apparently the ... ‘swanky medical stores’. These will be located at the entrance ... (BPL)’ card holders..., ,Mr Ashok said that these ...
... approval to formation of a Health Task Force for India.//, ... in the health sector in India which includes doctors, nurses ... commission on macroeconomics and health in its report,” a statement ... were also growing opportunities with India emerging as a major ...
Cached Medicine News:Health News:Drugs Are Effective In Treating Depression and Preventing Recurrence 2Health News:Gene That Causes Dry Skin, Identified 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: